
Posters
Defactinib Posters
Irina M. Shapiro, Jiangwen Zhang, Alan G. Derr, Christian M. Vidal, Alissa A. Neill, Qunli Xu, Daniel W. Paterson, Jonathan A. Pachter and David T. Weaver
April 02, 2012
LB-197; American Association for Cancer Research Annual Meeting
Jonathan A. Pachter, Jennifer E. Ring, Vihren N. Kolev, Alissa A. Neill, Christian M. Vidal, Brian T. Sullivan, Kevin T. Sprott, Mahesh V. Padval and Qunli Xu
April 02, 2012
LB-194; American Association for Cancer Research Annual Meeting
Qunli Xu, Christian M. Vidal, Jennifer E. Ring, Vihren N. Kolev, Irina M. Shapiro, Alissa A. Neill, Kevin T. Sprott, Mitchell Keegan, Daniel W. Paterson, Mahesh V. Padval and Jonathan A. Pachter.
April 02, 2012
LB-192; American Association for Cancer Research Annual Meeting
David T. Weaver, Irina M. Shapiro, Alan G. Derr, Daniel W. Paterson, Jonathan A. Pachter
June 04, 2012
1057; American Society of Clinical Oncology
Irina M. Shapiro, Vihren N. Kolev, Christian M. Vidal, Mitchell Keegan1, Qunli Xu, Craig Menges, Joseph R. Testa and Jonathan A. Pachter
September 14, 2012
P1.14; International Mesothelioma Interest Group
Jonathan A. Pachter, Vihren N. Kolev, Alissa A. Neill, Quentin Wright, Mahesh V. Padval & Qunli Xu
November 09, 2012
405; 2012 EORTC/AACR Molecular Targets Meeting
Qunli Xu, Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Irina M. Shapiro, Jennifer E. Ring, Mahesh V. Padval, Mitchell Keegan, and Jonathan A. Pachter
November 09, 2012
400; 2012 EORTC/AACR Molecular Targets Meeting
Jennifer E. Ring, Vihren N. Kolev, Christian M. Vidal, Irina M. Shapiro, Mahesh V. Padval, Mitchell Keegan, Jonathan A. Pachter, and Qunli Xu
December 08, 2012
P6-11-07; 2012 San Antonio Breast Cancer Symposium
Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Irina M. Shapiro, Mahesh V. Padval, Mitchell Keegan, Qunli Xu and Jonathan A. Pachter
December 08, 2012
P6-11-09; 2012 San Antonio Breast Cancer Symposium
Vihren N. Kolev, Quentin G. Wright, David T. Weaver, Jennifer E. Ring, Christian M. Vidal, Mahesh V. Padval, Jonathan A. Pachter and Qunli Xu
April 07, 2014
AACR 2014
Qunli Xu, Vihren N. Kolev, Quentin G. Wright, Jennifer E. Ring, Christian M. Vidal, Irina M. Shapiro, David T. Weaver, Mahesh V. Padval and Jonathan A. Pachter
April 07, 2014
AACR 2014
Anthony F. Trombino, Mahesh V. Padval, Quentin F. Wright and Qunli Xu
April 07, 2014
AACR 2014
Paul Baas1, Dean Fennell2, Richard J. Gralla3, Hedy Kindler4, Lee M. Krug5, Anna K. Nowak6, Lawrence H. Schwartz7, Mitchell Keegan8, Joanna C. Horobin8
October 23, 2014
iMig, Cape Town October 2014
- The Netherlands Cancer, Amsterdam NL; 2. University of Leicester, Leicester UK; 3. Albert Einstein College of Medicine, Bronx, NY USA; 4. University of Chicago, Chicago, IL USA; 5. Memorial Sloan-Kettering Cancer Center, New York, NY USA; 6. University of Western Australia, Perth, AU; 7. Columbia University College of Physicians and Surgeons, New York USA; 8. Verastem, Needham, MA USA
Qunli Xu1, Winnie F. Tam1, Christian M. Vidal1, Vihren N. Kolev1, Yuwaraj Kadariya2, Craig W. Menges2, Joseph R. Testa2, and Jonathan A. Pachter1
November 21, 2014
EORTC, Barcelona November 2014
1Verastem Inc., Boston, MA; 2Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA
Vihren N. Kolev1, Mahesh V. Padval1, Quentin G.Wright1, Jill Ricono2, David T. Weaver1, Jonathan A. Pachter1, and Qunli Xu1
November 21, 2014
EORTC, Barcelona November 2014
1Verastem Inc., Boston, MA; 2Molecular Response, San Diego, CA
1Toshio Shimizu, MD, PhD, 2Hidemi Aida, PhD, 2Chiaki Hashii, 3Joanna Horobin, MB, ChB, 3Mitchell Keegan, PhD, 3Mahesh Padval, PhD, 3Anne Poli, 3Lindsey Wilson, 1Kazuhiko Nakagawa, MD, PhD
November 21, 2014
EORTC, Barcelona November 2014
1Phase 1 Clinical Trials Program, Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan; 2Japan Clinical Research Operations (JCRO), Tokyo, Japan; 3Verastem, Inc., Boston, MA, USA
Jonathan A. Pachter1, Vihren N. Kolev1, Laurel Schunselaar3, Irina M. Shapiro1, Raphael Bueno2, Paul Baas3, David T. Weaver1 and Qunli Xu1
November 21, 2014
EORTC, Barcelona November 2014
1Verastem Inc., Boston, MA; 2Brigham & Women’s Hospital, Boston, MA; 3Netherlands Cancer Institute, Amsterdam
Winnie F. Tam, PhD, Jennifer E. Ring, Anthony F. Trombino, PhD, Jonathan A. Pachter, PhD, Mahesh V. Padval, PhD, Qunli Xu, PhD, David T. Weaver, PhD
December 07, 2014
56th ASH Annual Meeting & Exposition
Verastem Inc., Boston, MA
Y Zhang, M Moschetta, D Huynh, YT Tai, Y Zhang, W Zhang, Y Mishima, JE. Ring, WF Tam, Q Xu, P Maiso, M Reagan, I Sahin, A Sacco, S Manier, Y Aljawai, S Glavey, NC Munshi, KC Anderson, J Pachter, AM. Roccaro, IM. Ghobrial Dana
December 07, 2014
56th ASH Annual Meeting & Exposition
Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA; Verastem Inc., Cambridge, MA
Mark B. Meads1, Bin Fang2, Linda Mathews1, Jennifer Gemmer1, Liang Nong1, Ismael Rosado – Lopez1, Tuan Nguyen1, Jennifer E. Ring7, William Matsui5, A. Robert MacLeod6 , Jonathan A. Pachter7, Lori A. Hazlehurst3, John M. Koomen2,3, and Kenneth H. Shain1,4
December 07, 2014
56th ASH Annual Meeting & Exposition
Departments of Chemical Biology and Molecular Medicine 1, Proteomics 2, Molecular Oncology 3, and Malignant Hematology 4 at Moffitt Cancer Center and Research Institute, Tampa, Florida 5, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland 6 ISIS Pharmaceuticals, Carlsbad, California & 7 Verastem, Inc, Needham, Massachusetts
Barbara Muz1, Maurizio Buggio1, Feda Azab1, Anthony F. Trombino2, Mahesh Padval2 and Abdel Kareem Azab1
December 08, 2014
56th ASH Annual Meeting & Exposition
1Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis MO, USA; 2 Verastem, Inc., Boston MA, USA
Vihren N. Kolev1, Sean McDermott2, Max Wicha2, Jonathan A. Pachter1, Qunli Xu1, David T. Weaver1
December 14, 2014
San Antonio Breast Cancer Symposium
1Verastem, Inc., Boston, MA, 2University of Michigan Cancer Center, Ann Arbor, MI
Vihren N. Kolev, Qunli Xu, Mahesh Padval, Jonathan A. Pachter and David T. Weaver Verastem Inc., Boston, MA
April 20, 2015
AACR Annual Meeting 2015
Jonathan A. Pachter1, Vihren N. Kolev1, Laurel Schunselaar2, Mahesh V. Padval1, Irina M. Shapiro1, Raphael Bueno3, Paul Baas2, Qunli Xu1, and David T. Weaver1
April 20, 2015
AACR Annual Meeting 2015
1Verastem Inc., Boston, MA; 2Brigham & Women’s Hospital, Boston, MA; 3Netherlands Cancer Institute, Amsterdam
Udai Banerji1, Dean Anthony Fennell2, Hedy Lee Kindler3, Marjorie Glass Zauderer4, Mitchell Keegan5, Lou Vaickus5
September 09, 2015
2015 IASLC World Conference on Lung Cancer
VS-6063-104: A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTORInhibitor, Administered with a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects with Relapsed Malignant Mesothelioma
1 Royal Marsden Hospital, Sutton Surrey, UK; 2 University of Leicester, Leicester, UK; 3 University of Chicago, Chicago, IL, USA; 4 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 5 Verastem Inc., Boston, MA, USA
Hedy Lee Kindler1, Dean Fennell2, Paul Baas3, Marjorie Zauderer4, Anna K. Nowak5, Richard J. Gralla6, Takashi Nakano7, Marcelyne Joseney-Antoine8, Anne Poli8, Mitchell Keegan8, Lou Vaickus8
September 09, 2015
2015 World Conference on Lung Cancer
COMMAND: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Defactinib as Maintenance Therapy in Subjects with Malignant Pleural Mesothelioma which has Not Progressed on at least 4 Cycles of Pemetrexed/Platinum Therapy
1 University of Chicago, Chicago, USA; 2 University of Leicester, Leicester, United Kingdom; 3 Netherlands Cancer Institute, Amsterdam, Netherlands; 4 Memorial Sloan-Kettering Cancer Center, NYC, USA; 5 University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, Australia; 6 Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA; 7 Hyogo College of Medicine, Hyogo, Japan; 8 Verastem, Inc., Boston, USA
Jennifer E. Ring1, Yajuan Li1, Kam Sprott1, Irina M. Shapiro1, David DeNardo2, Yan Wang1, David T. Weaver1, and Jonathan A. Pachter1
November 05, 2015
SITC 2015
1Verastem Inc., Boston, MA; 2Washington University, St. Louis, MI
Vice President of Development, Verastem, Inc.
Hong Jiang1,5, Samarth Hegde1,5, Brett L. Knolhoff1,5, Yu Zhu1,5, John Herndon1,5, Esther Leu4, William Hawkins3,6, Irina M. Shapiro7, David T. Weaver7, Jonathan A. Pachter7, Andrea Wang-Gillam1,6, and David G. DeNardo1,2,5,6
November 05, 2015
SITC 2015
1Department of Medicine, 2Department of Pathology and Immunology, 3Department of Surgery, 4Division of Biostatistics, 5ICCE Institute, 6Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
7Verastem Inc., Needham, Massachusetts 02494, USA
November 06, 2015
EORTC 2015
Alan Serrels,1,2 Tom Lund,1 Bryan Serrels,1 Adam Byron,1 Rhoanne C. McPherson,2 Alexander von Kriegsheim,1 Laura Gómez-Cuadrado,1 Marta Canel,1 Morwenna Muir,1 Jennifer E. Ring,3 Eleni Maniati,4 Andrew H Sims,1 Jonathan A. Pachter,3 Valerie G. Brunton,1 Nick Gilbert,5 Stephen M. Anderton,2 Robert J.B. Nibbs,6 and Margaret C. Frame1
Hong Jiang1,5, Samarth Hegde1,5, Brett L. Knolhoff1,5, Yu Zhu1,5, John Herndon1,5, Esther Leu4, William Hawkins3,6, Irina M. Shapiro7, David T. Weaver7, Jonathan A. Pachter7, Andrea Wang-Gillam1,6, and David G. DeNardo1,2,5,6
Jennifer E. Ring1, Yajuan Li1, Kam Sprott1, Irina M. Shapiro1, David DeNardo2, Yan Wang1, David T. Weaver1, and Jonathan A. Pachter1
November 06, 2015
EORTC 2015
1Verastem Inc., Boston, MA; 2Washington University, St. Louis, MI
Vihren N. Kolev, Yan Wang, Kam Sprott, Irina Shapiro, Jennifer Ring, Jonathan A. Pachter, David T. Weaver
November 06, 2015
EORTC 2015
Verastem Inc., Needham, Massachusetts 02494, USA
April 18, 2016
AACR 2016
Lisa M. Bean1*, Florian J. Sulzmaier1*, Isabelle Tancioni1, Sean Uryu1, Christine Jean1, Xiao Lei Chen1, Elizabeth G. Kleinschmidt1, Kristen M. Anderson1, Edward A. Cordasco1, Joshua Axelrod1, Vihren N. Kolev2, Jonathan A. Pachter2, Dwayne G. Stupack1 and David D. Schlaepfer1
April 18, 2016
AACR 2016
Yan Wang1, Jennifer E. Ring1, Kam Sprott1, David DeNardo2, David T. Weaver1 and Jonathan A. Pachter1
Although durable responses to single agent immune checkpoint inhibitors have been reported, additional approaches are needed to extend this therapeutic benefit to a greater proportion of patients. Combination of immunotherapy agents with tumor microenvironment modulators has the potential to overcome barriers that tumor cells develop to evade the immune system, and provide benefit to a greater proportion of patients. Focal Adhesion Kinase (FAK) and the family member PYK2 are potentially valuable targets due to their roles in regulating key cellular populations in the tumor microenvironment. In addition to targeting cancer stem cells, the FAK/PYK2 dual inhibitors, VS-6063 and VS- 4718, have been shown to inhibit monocyte-derived macrophages, reduce tumor-associated macrophages in xenograft models, and promote a CD8+ T cell-mediated anti-tumor response in squamous cell carcinoma models.
1 Verastem Inc., Boston, MA; 2 Washington University, St. Louis, MO
December 10, 2017
Xiangmeng Wang [1], [2] , Po Yee Mak [1], Mu Hong [1], Wenjing Tao [1], Jonathan Pachter [3], David Weaver [3], Bing Xu [4], Michael Andreeff [1], Bing Z Carter [1].
[1] Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; [2] Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R.China; [3] Verastem, Inc, Needham, MA; [4] Department of Hematology, The first Affiliated Hospital of Xiamen University, Xiamen, P.R.China
Presenter: Xiangmeng Wang, Ph.D., MD Anderson Cancer Center
Abstract Number/Publication ID: 2653
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Date and Time: Sunday, December 10, 2017 from 6:00-8:00 PM ET
Location: Georgia World Congress Center, Building A, Level 1, Hall A2
Defactinib Presentations
Mitchell Keegan, VP Development – Verastem
October 23, 2014
iMig, Cape Town October 2014
Raphael Bueno1, Ritu R Gill1, Julianne Barlow1, David M Jackman1, Beow Y Yeap1, David Weaver2, Mahesh Padval2, Rachel Sorensen2, Mitchell Keegan2
October 23, 2014
iMig, Cape Town October 2014
- Brigham and Women’s Hospital, Boston, MA, USA; 2. Verastem, Inc., Boston, MA, USA
Paul Baas, Department of Thorax Oncology Netherlands Cancer Institute, Amsterdam
October 23, 2014
iMig, Cape Town October 2014
December 08, 2014
56th ASH Annual Meeting & Exposition
Mitchell Keegan
September 09, 2015
2015 World Conference on Lung Cancer
Vice President of Development, Verastem, Inc.
Jonathan Pachter
September 09, 2015
2015 World Conference on Lung Cancer
Vice President of Research, Verastem, Inc.
David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly, Suresh S. Ramalingam, David R. Spigel, Woondong Jeong, Pier Scaglioni, Marilyn Li, Mitchell Keegan, Joanna C. Horobin, Timothy F. Burns
September 09, 2015
2015 World Conference on Lung Cancer
David Weaver
September 09, 2015
2015 World Conference on Lung Cancer
Vice President of Translational Research, Verastem, Inc.
Jonathan Pachter, VP/Head of Research, Verastem
March 10, 2016
Keystone Symposium on Stem Cells and Cancer
March 22, 2016
Annual Meeting on Women’s Cancer | SGO
Raphael Bueno, M.D.
May 03, 2016
The International Mesothelioma Interest Group (iMig)
Mini Symposium 10: Novel Targets – Entering in the Clinic (Track: Early Phase Clinical Trials)
Keystone Symposium on Cancer Pathophysiology
Lead Author: Bing Carter, Ph.D., Associate Professor, Department of Leukemia – Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
December 04, 2016
American Society of Hematology (ASH) 2016 Annual Meeting
Location: San Diego Convention Center, Hall GH
Date and Time: Saturday, December 3, 2016, 5:30 – 7:30 pm PT
David G. DeNardo, PhD. Department of Medicine, Department of Path/Immunology
April 02, 2017
AACR 2017
Duvelisib Posters
June 26, 2017
E-Poster Presentation
Title: DYNAMO: The Clinical Activity of Duvelisib in Patients with Double-Refractory Small Lymphocytic Lymphoma in a Phase 2 Study
Abstract code: E1130
Topic: Indolent Non-Hodgkin lymphoma – Clinical
Location: e-poster screens
Date and time: Friday, June 23, 2017 from 9:30 CET to Saturday, June 24, 2017 at 19:00 CET
Jonathan Pachter, Ph.D., Verastem
December 09, 2017
Title: The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model
Presenter: Jonathan Pachter, Ph.D., Verastem
Abstract Number/Publication ID: 1541
Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I
Date and Time: Saturday, December 9, 2017 from 5:30-7:30 PM ET
Location: Georgia World Congress Center, Building A, Level 1, Hall A2
Alison J. Moskowitz MD, Raphael Koch MD, Neha Mehta-Shah MD, Patricia Myskowski MD, Meenal Kheterpal MD, Ahmet Dogan MD PhD, Theresa Davey MPAS, Natasha Galasso BA, Marzouk Evan BA, Monica Shah BA, Nivetha Ganesan BS, Lakeisha Lubin BS, Youn H. Kim MD, Michael Khodadoust MD PhD, Timothy Almazan MD, Julia Dai MD, Eric D. Jacobsen MD, David M. Weinstock MD, and Steven M. Horwitz MD
December 11, 2017
Presenter: Steven Horwitz, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number/Publication ID: 819
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: T-Cell Lymphoma Clinical Studies; Monday, December 11, 2017 from 4:30-6:00 PM ET
Date and Time: Monday, December 11, 2017 at 5:00 PM ET
Location: Georgia World Congress Center, Building A, Level 4, Marcus Auditorium
Jonathan A. Pachter and David T. Weaver
January 26, 2018
Presenter: Jonathan A. Pachter and David T. Weaver
Poster: 33
Session: ASCO-SITC Clinical Immuno-Oncology Symposium
Date and Time: January 26, 2018
Location: San Francisco, California, USA
Duvelisib Presentations
Carla Casulo, M.D., Assistant Professor, Wilmot Cancer Institute, University of Rochester
December 04, 2016
American Society of Hematology (ASH) 2016 Annual Meeting
Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 4, 2016, 6:00 – 8:00 pm PT
Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt, Z Nagy, O Tournilhac, KE Abou-Nassar, M Crump, ED Jacobsen, S de Vos, P Santabarbara, W Shi, L Steelman, ND Wagner-Johnston
December 05, 2016
American Society of Hematology (ASH) 2016 Annual Meeting
Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 5, 2016, 6:15 pm PT
June 16, 2017
Duvelisib Monotherapy Treatment Demonstrates 47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma
88% of Patients had a Reduction in the Size of Target Lymph Nodes
Duvelisib Remains Well-Tolerated in Long-Term Follow Up
June 26, 2017
Oral Presentation
Title: DYNAMO: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Double-Refractory Follicular Lymphoma
Abstract code: S777
Topic: Indolent Non-Hodgkin lymphoma – Clinical
Session title: Follicular lymphoma – Clinical
Location: Hall C
Date and time: Sunday, June 25, 2017, 8:45 – 9:00 CET
December 10, 2017
Title: Results from the Phase 3 DUO™ Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Presenter: Ian Flinn, M.D., Ph.D., Sarah Cannon Research Institute
Abstract Number/Publication ID: 493
Session: 642. CLL: Therapy, excluding Transplantation: Targeting MRD Negative CLL with Combinations of Novel Agents and Chemoimmunotherapy Regimens, New Treatments; Sunday, December 10, 2017 from 4:30-6:00 PM ET
Date and Time: Sunday, December 10, 2017 at 4:30 PM ET
Location: Georgia World Congress Center, Building B, Level 5, Murphy BR 3-4